Abstracts tagged "Cohort Study"

Abstract Number: 0453 • ACR Convergence 2025
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
kyung-Ann Lee¹, Bora Lee², Hyun-Sook Kim³ and Se Hee Kim⁴, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Chosun University, GwangJu, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ⁴Kyung Hee University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
Abstract Number: 0209 • ACR Convergence 2025
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Yuanteng Li¹, Cheuk Leung², Heather Lin², Angeles Lopez-Olivio³ and Jean Tayar³, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, ³The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…
Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 2118 • ACR Convergence 2025
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Grace Hyeyeon Lee¹, Hamzah Amin² and marwan Bukhari¹, ¹University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Anticonvulsants are commonly used to manage neurological and psychiatric disorders such as epilepsy, migraines and bipolar disorder. These medications are often prescribed long-term, and…
Abstract Number: 1960 • ACR Convergence 2025
Item Response Theory to Develop an Ultrasound Composite Score for Knee Osteoarthritis Assessment
Liubov Arbeeva¹, Carolina Alvarez², Jonathan Samuels³, Janice Lin⁴, Minna Kohler⁵, Catherine Bakewell⁶, Todd Schwartz⁷ and Amanda Nelson⁸, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³NYU Langone, Rye Brook, NY, ⁴Stanford University, Palo Alto, CA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Intermountain Healthcare, Salt Lake City, UT, ⁷University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁸University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Semi-quantitative scoring systems have long been used for radiographic findings in osteoarthritis (OA), but limited work has utilized ultrasound (US). The aim of this…
Abstract Number: 1631 • ACR Convergence 2025
New Arterial Damage in Takayasu’s Arteritis
Tanaz Kermani¹, Sema Kaymaz-Tahra², Aysegul Avcu³, Fatma Alibaz-Oner⁴, Haner Direskeneli³ and Peter Merkel⁵, ¹University of California Los Angeles, Santa Monica, CA, ²Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ³Marmara University, Istanbul, Turkey, ⁴MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY, Istanbul, Turkey, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Damage is one of the consequences of disease and is often considered irreversible. This study aimed to evaluate new arterial damage in Takayasu’s arteritis…
Abstract Number: 1429 • ACR Convergence 2025
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
Savannah Bowman¹, Mei Li², Xiudong Lei³, Hui Zhao³, Juan Ruiz⁴, Sharon H. Giordano³, Alexis Ogdie⁵ and Maria Suarez-Almazor⁶, ¹Baylor College of Medicine, Houston, ²The University of Texas Health Science Center at Houston, Houston, ³The University of Texas MD Anderson Cancer Center, Houston, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵University of Pennsylvania, Philadelphia, PA, ⁶MD Anderson Cancer Center, Houston, TX
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with several comorbidities, including cancer. Prior studies have shown that elderly patients with rheumatoid arthritis and concomitant breast or…
Abstract Number: 1125 • ACR Convergence 2025
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
Brian Coburn¹, Daniel Wright², Jeff Newcomb³, Mary Brophy⁴, Anne Davis-Karim⁵, Ryan Ferguson⁴, Michael Pillinger⁶, Tuhina Neogi⁷, Paul Palevsky⁸, Bryant England³, James O'Dell³, Lisa Stamp⁹, Ted Mikuls³ and Joshua Baker¹⁰, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Otago, Dunedin, New Zealand, ³University of Nebraska Medical Center, Omaha, NE, ⁴VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁵VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Boston University School of Medicine, Boston, MA, ⁸VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁹University of Otago, Christchurch, Christchurch, New Zealand, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 0201 • ACR Convergence 2025
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Ana Victoria Esteban Vázquez¹, Martina Steiner², Cristina Vergara², Elisabet Castañeda Estévez³, Maria Beatriz Paredes Romero⁴, Isabel De La Camara-Fernandez¹, Laura Trives¹, Tatiana Cobo¹, Patricia Richi⁵, Maria liz Romero⁵, Marta De San Segundo³, Antonio Sanchis³, Carolina Marín⁶, Maria Teresa Navio Marco⁷ and Santiago Muñoz¹, ¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Infanta Sofía University Hospital, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁷Infanta Leonor Universitary Hospital, Madrid, Spain
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) receiving Janus Kinase Inhibitors (JAKi) are at increased risk of herpes zoster reactivation. The adjuvanted recombinant zoster vaccine…
Abstract Number: 2698 • ACR Convergence 2025
Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Yun Kyu Kim¹, Hajeong Lee², Jun Won Park³, Eun Bong Lee³, You-Jung Ha⁴ and Jin Kyun Park², ¹Seoul National University, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, South Korea, ⁴Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: The efficacy of calcineurin inhibitors in the induction treatment of lupus nephritis (LN) has been increasingly supported by recent studies. Based on these findings,…
Abstract Number: 2438 • ACR Convergence 2025
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Ahmad Alomari¹, Asim Khanfar², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²Rochester General Hospital, Rochester, NY, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…
Abstract Number: 2115 • ACR Convergence 2025
METHOFRACT, a methotrexate osteopathy multicentric binational cohort study.
François ROBIN¹, Roba Ghossan², Nadia Mehsen-Cetre³, Louise Triquet¹, Guillaume LARID⁴, Guillaume Coiffier⁵, Marine Mina⁶, Marie-Eva Pickering⁷, Claire Barthe⁸, Julien Paccou⁹, Julien Herman¹⁰, Emmanuel Massy¹¹, Isabelle Roitg¹², Martine Branquet¹³, Julien Lasnier Siron³, Manon Guillouard¹⁴, Camille Desmonet Trousset¹⁵, Aurore Aubrun¹⁶, Bertrand Godfrin¹⁷, Jean-Philippe Hauzeur¹⁸, Emmanuel Chatelus¹⁹, Eugénie Koumakis², Jean-Louis Legrand²⁰, Thierry Schaeverbeke³, Alexia Leloix¹, Maeva Masson²¹, Julia Nicolau¹⁵, Charles Ghiringhelli²², Marijke Decrock¹², Durel Cécile-Audrey²³, Béatrice Bouvard²⁴, Bernard Cortet⁹, Charlotte Casadepax-Soulet²⁵, Olivier Malaise⁶, Rose Marie Javier²⁶, Karine Briot² and Pascal Guggenbuhl¹, ¹Rennes University Hospital, Rennes, France, ²APHP, Paris, France, ³Bordeaux University Hospital, Bordeaux, France, ⁴Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ⁵Dinan Hospital, Dinan, France, ⁶Liege University Hospital, Liège, Belgium, ⁷Clermon-Ferrand University Hospital, Clermont-Ferrand, France, ⁸Clinique Tivoli Ducos, Bordeaux, France, ⁹Lille University Hospital, Lille, France, ¹⁰La Roche Sur Yon Hospital, La Roche-sur-Yon, France, ¹¹Lyon University Hospital, Lyon, France, ¹²Perpignan Hospital, Perpignan, France, ¹³Ploemeur Rheumatology Liberal Structure, Ploemeur, France, ¹⁴Aurillac Hospital, Aurillac, France, ¹⁵Dieppe Hospital, Dieppe, France, ¹⁶Nice Rheumatology Liberal Stucture, Nice, France, ¹⁷St Gaudens Rheumatology Liberal Structure, St Gaudens, France, ¹⁸Liege University Hospital, Liege, Belgium, ¹⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ²⁰Arras Hospital, Arras, France, ²¹Toulouse University Hospital, Toulouse, France, ²²Pauillac Rheumatology Liberal Structure, Pauillac, France, ²³Saint Joseph Saint Luc Hospital, Lyon, France, ²⁴Angers University Hospital, Angers, France, ²⁵West Reunion Hospital, Saint Paul, France, ²⁶Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Methotrexate-induced osteopathy is a rare condition. The clinical presentation is often typical, associating lower limb involvement with metaphyseal bone fractures/cracks, mainly of the tibia…

« Previous Page
1
…
7
8
9
10
11
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].